BR9912937A - Pró-drogas de inibidores de bomba de prótons - Google Patents

Pró-drogas de inibidores de bomba de prótons

Info

Publication number
BR9912937A
BR9912937A BR9912937-0A BR9912937A BR9912937A BR 9912937 A BR9912937 A BR 9912937A BR 9912937 A BR9912937 A BR 9912937A BR 9912937 A BR9912937 A BR 9912937A
Authority
BR
Brazil
Prior art keywords
proton pump
drugs
prodrugs
pump inhibitor
benzimidazole
Prior art date
Application number
BR9912937-0A
Other languages
English (en)
Inventor
Michael Garst
Georg Sachs
Jai Moo Shin
Original Assignee
Partnership Of Michael E Garst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/131,481 external-priority patent/US6093734A/en
Application filed by Partnership Of Michael E Garst filed Critical Partnership Of Michael E Garst
Publication of BR9912937A publication Critical patent/BR9912937A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Reciprocating Pumps (AREA)
  • Fertilizing (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)

Abstract

Patente de Invenção: <B>"PRó-DROGAS DE INIBIDORES DE BOMBA DE PRóTONS"<D>. As pró-drogas de drogas inibidoras de bomba de prótons de tipo piridil metil sufinil benzimidazol tem um grupo sulfinila ou arilsulfonila hidrolisável fixado ao nitrogênio benzimidazol, ou incluem um grupo que forma uma base Mannich com o nitrogênio benzimidazol. As pró-drogas da invenção hidrolisam sob condições fisiológicas para prover os inibidores de bomba de prótons com uma meia-vida mensurável em horas, e são capazes de prover concentrações de plasma prolongadas das drogas inibidores de bomba de prótons durante um tempo mais longo do que as drogas atualmente usadas. A geração de drogas inibidoras de bomba de prótons a partir das pró-drogas da invenção sob condições fisiológicas permite um tratamento mais eficaz de várias doenças e condições causadas por secreção de ácido gástrico.
BR9912937-0A 1998-08-10 1999-08-09 Pró-drogas de inibidores de bomba de prótons BR9912937A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/131,481 US6093734A (en) 1998-08-10 1998-08-10 Prodrugs of proton pump inhibitors
US36438199A 1999-07-29 1999-07-29
PCT/US1999/018048 WO2000009498A1 (en) 1998-08-10 1999-08-09 Prodrugs of proton pump inhibitors

Publications (1)

Publication Number Publication Date
BR9912937A true BR9912937A (pt) 2001-05-08

Family

ID=26829517

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9912937-0A BR9912937A (pt) 1998-08-10 1999-08-09 Pró-drogas de inibidores de bomba de prótons

Country Status (28)

Country Link
US (1) US6559167B1 (pt)
EP (1) EP1105387B1 (pt)
JP (1) JP4346243B2 (pt)
KR (1) KR100472126B1 (pt)
CN (1) CN100396675C (pt)
AT (1) ATE231857T1 (pt)
AU (1) AU752292B2 (pt)
BG (1) BG64870B1 (pt)
BR (1) BR9912937A (pt)
CA (1) CA2338311C (pt)
DE (1) DE69905171T2 (pt)
DK (1) DK1105387T3 (pt)
ES (1) ES2192394T3 (pt)
FI (1) FI20010248A (pt)
HK (1) HK1035368A1 (pt)
HR (1) HRP20010106A2 (pt)
HU (1) HUP0103464A3 (pt)
ID (1) ID28273A (pt)
IL (2) IL141083A0 (pt)
IS (1) IS5826A (pt)
MX (1) MXPA01001464A (pt)
NO (1) NO322490B1 (pt)
NZ (1) NZ510180A (pt)
PL (1) PL346000A1 (pt)
TR (1) TR200100431T2 (pt)
UA (1) UA67788C2 (pt)
WO (1) WO2000009498A1 (pt)
YU (1) YU10101A (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050020637A1 (en) * 2001-11-19 2005-01-27 Wolfgang-Alexander Simon Agents for the treatment of airway disorders
ES2263028T3 (es) 2002-07-19 2006-12-01 Winston Pharmaceuticals Llc Derivados de bencimidazol y su uso como profarmacos de inhibidores de bomba de proton.
JP2006188432A (ja) * 2003-02-25 2006-07-20 Zeria Pharmaceut Co Ltd 四環系スルフェンアミド化合物
PL379542A1 (pl) * 2003-07-15 2006-10-02 Allergan, Inc. Sposób wytwarzania izomerycznie czystych proleków inhibitorów pompy protonowej
KR20060118421A (ko) * 2003-08-29 2006-11-23 다이노젠 파마세우티컬스, 인코포레이티드 위장 운동 장애의 치료에 유용한 조성물
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
WO2005039640A1 (en) * 2003-10-03 2005-05-06 Allergan Inc. Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump inhibitor prodrugs
WO2005082337A2 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Compositions comprising prodrugs of proton pump inhibitors
JP2007523164A (ja) * 2004-02-18 2007-08-16 アラーガン、インコーポレイテッド プロトンポンプインヒビターに関連する化合物の静脈内投与のための方法および組成物
US20050239845A1 (en) * 2004-04-16 2005-10-27 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
EP1740571B1 (en) * 2004-04-28 2009-07-29 Hetero Drugs Limited A process for preparing pyridinylmethyl-1h- benzimidazole compounds in enantiomerically enriched form or as single enantiomers
DE602004025386D1 (de) * 2004-05-28 2010-03-18 Hetero Drugs Ltd Neue stereoselektive synthese von benzimidazolsulfoxiden
CA2570968A1 (en) * 2004-06-17 2006-01-26 Wyeth Gonadotropin releasing hormone receptor antagonists
US7714130B2 (en) * 2004-06-17 2010-05-11 Wyeth Processes for preparing gonadotropin releasing hormone receptor antagonists
AU2005286593A1 (en) * 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyridine compounds, process for their preparation and compositions containing them
CA2587853A1 (en) * 2004-11-23 2006-06-01 Wyeth Gonadotropin releasing hormone receptor antagonists
US7538113B2 (en) * 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) * 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) * 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US20060189619A1 (en) * 2005-02-24 2006-08-24 Wyeth 3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds
US20070015782A1 (en) 2005-04-15 2007-01-18 Eisai Co., Ltd. Benzimidazole compound
US9040564B2 (en) 2005-04-28 2015-05-26 Eisai R&D Management Co., Ltd. Stabilized composition
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) * 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
US20090036406A1 (en) * 2005-06-13 2009-02-05 Takeda Pharmaceutical Company Limited Injection
WO2007073301A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Benzoimidazole derivatives as prodrugs of proton pump inhibitors
US20100113524A1 (en) * 2006-09-19 2010-05-06 Garst Michael E Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety
US20100317689A1 (en) * 2006-09-19 2010-12-16 Garst Michael E Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
EP2486910A3 (en) 2006-10-27 2012-08-22 The Curators Of The University Of Missouri Multi-chambered apparatus comprising a dispenser head
CN101497622B (zh) * 2008-01-30 2011-04-27 山东轩竹医药科技有限公司 吡啶甲基亚磺酰基咪唑并吡啶衍生物
EP2252274A4 (en) 2008-02-20 2011-05-11 Univ Missouri COMPOSITION COMPRISING A COMBINATION OF OMEPRAZOLE AND LANSOPRAZOLE, AND A BUFFER AGENT, AND METHODS OF USING THE SAME
UA100192C2 (en) * 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
RU2015122126A (ru) * 2012-11-19 2017-01-10 Цзянсу Хэнсох Фармасьютикал Ко., Лтд. Производное пиррол сульфонамида, метод его получения и применение в медицине
EP2963019B1 (en) 2013-02-28 2020-08-12 Takeda Pharmaceutical Company Limited Method for producing pyridine-3-sulfonyl chloride
PL3762368T3 (pl) 2018-03-08 2022-06-06 Incyte Corporation ZWIĄZKI AMINOPIRAZYNODIOLOWE JAKO INHIBITORY PI3K-γ
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
EP4154010A1 (en) 2020-05-20 2023-03-29 F. Hoffmann-La Roche AG Reagent for mass spectrometry

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416649B (sv) * 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4359465A (en) * 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
SE8300736D0 (sv) * 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
IL76839A (en) * 1984-10-31 1988-08-31 Byk Gulden Lomberg Chem Fab Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
SE8505112D0 (sv) * 1985-10-29 1985-10-29 Haessle Ab Novel pharmacological compounds
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
US4965269A (en) * 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
PL165898B1 (pl) * 1990-06-20 1995-02-28 Astra Ab Sposób wytwarzania nowych pochodnych dwualkoksyplrydynylobenzlmldazolu PL
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
US5945425A (en) * 1994-04-29 1999-08-31 G.D. Searle & Co. Method of using (H+ /K+)ATPase inhibitors as antiviral agents
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
SE9602442D0 (sv) 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals

Also Published As

Publication number Publication date
FI20010248A (fi) 2001-02-09
KR100472126B1 (ko) 2005-03-08
BG64870B1 (bg) 2006-07-31
TR200100431T2 (tr) 2001-06-21
IL141083A (en) 2006-07-05
YU10101A (sh) 2003-10-31
DK1105387T3 (da) 2003-06-23
ATE231857T1 (de) 2003-02-15
ES2192394T3 (es) 2003-10-01
JP4346243B2 (ja) 2009-10-21
BG105191A (en) 2001-12-29
ID28273A (id) 2001-05-10
DE69905171T2 (de) 2003-11-20
DE69905171D1 (de) 2003-03-06
AU5551899A (en) 2000-03-06
HUP0103464A2 (hu) 2002-02-28
EP1105387A1 (en) 2001-06-13
HRP20010106A2 (en) 2002-02-28
EP1105387B1 (en) 2003-01-29
NO322490B1 (no) 2006-10-09
NZ510180A (en) 2002-11-26
CN100396675C (zh) 2008-06-25
AU752292B2 (en) 2002-09-12
CA2338311C (en) 2007-01-23
PL346000A1 (en) 2002-01-14
NO20010693D0 (no) 2001-02-09
NO20010693L (no) 2001-03-05
IS5826A (is) 2001-01-29
MXPA01001464A (es) 2002-05-08
HUP0103464A3 (en) 2002-11-28
KR20010103566A (ko) 2001-11-23
IL141083A0 (en) 2002-02-10
UA67788C2 (uk) 2004-07-15
WO2000009498A1 (en) 2000-02-24
US6559167B1 (en) 2003-05-06
HK1035368A1 (en) 2001-11-23
JP2003534232A (ja) 2003-11-18
CN1312806A (zh) 2001-09-12
CA2338311A1 (en) 2000-02-24

Similar Documents

Publication Publication Date Title
BR9912937A (pt) Pró-drogas de inibidores de bomba de prótons
BR0109161A (pt) Beta-carbolinas substituìdas com atividade de inibição de ikb-quinase
ATE309194T1 (de) Neuartige dicarbonsäurederivate mit pharmazeutischen eigenschaften
UY26926A1 (es) Derivados de la quinolina y quinazolina
UY27646A1 (es) Derivados de quinolina como antagonistas de npt
BRPI0509282A (pt) compostos contendo hidrazida inibidores de cftr e seus usos
DE69731610D1 (de) Orale verabreichung wirksamer mengen von hyaluronsäure
HUP0402422A2 (hu) Deuterizált szubsztituált pirazolil-benzolszulfonamid-származékok, az ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
SE0401345D0 (sv) Therapeutic compounds: Pyridine as scaffold
BRPI0111591B8 (pt) composto, composição farmacêutica, e, usos de um composto
BR0309185A (pt) Medicamento contendo beta-miméticos e um novo anticolinérgico
IT1319202B1 (it) Farmaci per le malattie a base infiammatoria.
DE69927497D1 (de) Sulfonsäure- oder sulfonylamino-n-(heteroaralkyl)-azaheterozyklylamidverbindungen
AR017172A1 (es) Compuestos derivados de 3,4-diariltiazolina-2-ona o 2-tiona un metodo para su preparacion y composiciones farmaceuticas que los comprenden
TR200102811T2 (tr) Oral uygulama için, tolpersiyon içeren farmasötik preparat.
NO20043115L (no) Substituerte diketopiperaziner som oksytocin antagonister
BR0315662A (pt) Derivados de 1-(4-benzil-piperazin-1-il)-3-fenil-propenona
BR0200341A (pt) Bifenilsulfonamidas proveitosas como inibidores de metaloproteases da matriz
SE9902267D0 (sv) New compounds
BR0013582A (pt) Agonistas retinóides seletivos para rar
AR016382A1 (es) Uso de un derivado del acido bencil-indazol metoxialcanoico.
PT1178960E (pt) Analogos da vitamina d e sua utilizacao farmaceutica
EP3048886B1 (en) 3, 4-bis-benzylsulfonylbutanenitrile and its pharmaceutical use
CY1105308T1 (el) Θepαπεια για υπep-ουρικαιμια
EA200401082A1 (ru) Новые соединения бензоиндолина, способ их получения и фармацевтические композиции, которые их содержат

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: MICHAEL E. GARST (US), GEORGE SACHS (US), JAI MOO SHIN (US)

B25A Requested transfer of rights approved

Free format text: MICHAEL E. GARST (US), JAI MOO SHIN (US), THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US), U.S. GOVERNMENT REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US)

B25A Requested transfer of rights approved

Free format text: MICHAEL E. GARST (US), THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US), U. S. GOVERNMENT REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US)

B25A Requested transfer of rights approved

Free format text: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US), U.S. GOVERNMENT REPRESENTED BY THE DEPARTMENT OR VETERANS AFFAIRS (US), WINSTON PHARMACEUTICALS, LLC (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: C07D 401/12, C07D 235/28, A61K 31/4439, A61K 31/4184, C07D 401/14 C07D 409/14,C07D 417/14, C07D 471/07, A61K 31/4188, A61K 31/437, A61K 31/4427, A61K 31/4433, A61K 31/5377, A61P 1/04

Ipc: C07D 401/12 (2009.01), C07D 235/28 (2009.01), A61K

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE ACORDO COM ART. 8O, 11, 13, 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.